Big data challenge and opportunity for biopharmaceutical enterprises

It is now obvious that, big data will play key role in enabling scientists to discover life saving biologic drugs of the future.

In effect, opportunities are endless, and biopharmaceutical enterprises are generating huge volumes of data throughout the discovery, pre-clinical and clinical stages of development of new antibody based therapeutics.

Technology innovations such as high-throughput DNA sequencing have created a big data challenge and opportunity for enterprises involved in monoclonal antibody (mAb) therapeutic development. 

Multiple challenges in leveraging data include data accuracy, data completeness, difficulties combining data that comes from different sources and complexity of implementing data analytics.